

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-49. (Cancelled)

50. (Previously Presented) A crystalline Form IV {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone characterized by at least one of the following:

- a) a solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum comprising peaks at the following chemical shifts:  $52.3 \pm 0.2$  and  $195.4 \pm 0.2$  ppm;
- b) an X-ray powder diffraction pattern comprising at least two peaks wherein one peak is  $12.1 \pm 0.1^\circ$ , and the second peak is selected from the group consisting of  $8.3 \pm 0.1^\circ$ ,  $14.3 \pm 0.1^\circ$ ,  $16.6 \pm 0.1^\circ$ ,  $16.9 \pm 0.1^\circ$ , and  $18.5 \pm 0.1^\circ$  in  $2\theta$ ; and
- c) an X-ray powder diffraction pattern comprising at least the following peaks:  $8.3 \pm 0.1^\circ$ ,  $12.1 \pm 0.1^\circ$ ,  $16.6 \pm 0.1^\circ$ ,  $16.9 \pm 0.1^\circ$ , and  $18.5 \pm 0.1^\circ$  in  $2\theta$ .

51. (Previously Presented) A crystalline Form V {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone characterized by at least one of the following:

- a) a solid-state  $^{13}\text{C}$  nuclear magnetic resonance spectrum comprising peaks at the following chemical shifts:  $54.3 \pm 0.2$  and  $196.6 \pm 0.2$  ppm;
- b) an X-ray powder diffraction pattern comprising at least two peaks wherein one peak is  $12.5 \pm 0.1^\circ$ , and the second peak is selected from the group consisting of  $15.8 \pm 0.1^\circ$ ,  $16.5 \pm 0.1^\circ$ ,  $19.1 \pm 0.1^\circ$ ,  $19.7 \pm 0.1^\circ$ ,  $21.5 \pm 0.1^\circ$ ,  $25.3 \pm 0.1^\circ$ ,  $27.7 \pm 0.1^\circ$  and  $28.6 \pm 0.1^\circ$  in  $2\theta$ ; and
- c) an X-ray powder diffraction pattern comprising at least the following peaks:  $12.5 \pm 0.1^\circ$ ,  $25.3 \pm 0.1^\circ$ ,  $27.7 \pm 0.1^\circ$ , and  $28.6 \pm 0.1^\circ$  in  $2\theta$ .

52. (Withdrawn) A compound that is (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone, or a salt thereof.

53. (Withdrawn) The compound of **Claim 52**, which is (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone phosphate.

54. (Previously Presented) A process for preparing a compound that is {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, comprising reacting (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone or a phosphate salt thereof with 1-azidomethyl-3,5-bis(trifluoromethyl)benzene in the presence of a suitable base and a solvent.

55. (Previously Presented) The process of **Claim 54** wherein the base is potassium carbonate.

56. (Previously Presented) The process of **Claim 55** wherein the solvent is selected from the group consisting of dimethylsulfoxide, isopropanol, ethanol, tetrahydrofuran, and toluene.

57. (Previously Presented) A process for preparing the compound of **Claim 50** comprising crystallization of {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone from a solvent.

58. (Previously Presented) The process of **Claim 57** wherein the solvent is selected from the group consisting of isopropanol, acetone, acetonitrile, propanol, butanol, ethyl acetate, methyl tertiary butyl ether, and dichloromethane.

59. (Previously Presented) A process for preparing the compound of **Claim 50** comprising crystallization of {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone by solution-mediated phase transformation.

60. (Previously Presented) A process for preparing the compound of **Claim 51** comprising crystallization of {2-[1-(3,5-bis(trifluoromethyl)benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone from a mixture of a solvent and an anti-solvent.

61. (Previously Presented) The process of **Claim 60** wherein the solvent is methanol or ethanol.

62. (Previously Presented) The process of **Claim 61** wherein the anti-solvent is water.

63. (Currently Amended) A solid pharmaceutical composition comprising a crystalline compound of **Claim 50**, in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents.

64. (Previously Presented) The composition of **Claim 63** comprising at least one of the following: mannitol, microcrystalline cellulose, hydroxypropylcellulose, colloidal silicon dioxide, croscarmellose sodium, and stearic acid.

65. (Previously Presented) The composition of **Claim 64** further comprising an anionic surfactant in combination with an acid.

66. (Previously Presented) The composition of **Claim 65** wherein the anionic surfactant is sodium laurylsulfate and wherein the acid is citric acid.

67. (Currently Amended) A solid pharmaceutical composition comprising a crystalline compound of **Claim 51**, in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents.

68. (Previously Presented) The composition of **Claim 67** comprising at least one of the following: mannitol, microcrystalline cellulose, hydroxypropylcellulose, colloidal silicon dioxide, croscarmellose sodium, and stearic acid.

69. (Previously Presented) The composition of **Claim 68** further comprising an anionic surfactant in combination with an acid.

70. (Previously Presented) The composition of **Claim 69** wherein the anionic surfactant is sodium laurylsulfate and wherein the acid is citric acid.